As previously reported, Roche (RHHBY) said it is ready to immediately resume new orders and shipments of Sarepta’s (SRPT) Elevidys for ambulatory patients outside of the U.S. following the FDA’s decision to remove the voluntary hold on Elevidys for ambulatory Duchenne Muscular Dystrophy patients in the U.S. Roche stated that to date about 760 ambulatory DMD patients have been treated with Elevidys and reports that to date there have been no treatment-related fatalities in ambulatory DMD patients, according to Reuters, citing the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche says set to resume shipments of Sarepta’s Elevidys outside U.S.
- Roche Holding AG’s Earnings Call Highlights Growth and Challenges
- Trump administration mulls charging patent holders 1%-5% fee, WSJ reports
- Roche price target raised to CHF 230 from CHF 220 at JPMorgan
- Genentech to present new data from Alzheimer’s development portfolio